No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BTAI240517P3000
- 0.65
- 0.000.00%
15min DelayClose May 9 15:59 ET
0.65High0.65Low
0.65Open0.65Pre Close5 Volume243 Open Interest3.00Strike Price325.00Turnover0.00%IV4.12%PremiumMay 17, 2024Expiry Date0.70Intrinsic Value100Multiplier7DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma3.84Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Bullish Outlook: Bioxcel Therapeutics' Revenue Surge and Promising Clinical Trials Fuel Buy Rating
Q1 2024 BioXcel Therapeutics Inc Earnings Call
Express News | BioXcel Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript
BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript
BioXcel Therapeutics | 10-Q: Quarterly report
BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.04) by 16.35 percent. This is a 52.72 percent increase over losses of
Comments
$BioXcel Therapeutics(BTAI.US$BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate
1
$BioXcel Therapeutics(BTAI.US$
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...
2
$BioXcel Therapeutics(BTAI.US$ BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
1
$BioXcel Therapeutics(BTAI.US$ BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
13 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
13 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
1
1
Read more